Recent Republican-led legislative changes delay Medicare drug price negotiations for costly cancer treatments, maintaining high patient costs and impacting seniors and disabled Americans.
CMS is considering a pilot program to cover GLP-1 drugs for obesity under Medicare and Medicaid, reversing earlier policy. This evolving coverage changes obesity drug access for patients and payers.
The Trump administration proposes a Medicare and Medicaid pilot program for covering GLP-1 weight loss drugs, marking a key shift in healthcare policy and potential budget impacts.
The Supreme Court's 2025 ruling affirms ACA preventive service coverage, shaping pharmaceutical, diagnostic, and insurance sector investments amid evolving HHS regulations.
Novo Nordisk expands access to Wegovy with a new self-pay pricing program and pursues legal actions against unauthorized compounded drug sales, impacting the obesity treatment market.
Pfizer and other pharmaceutical firms have discussed most-favored-nation drug pricing with the U.S. government, highlighting potential impacts on insurance and payer strategies.
CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.
Comprehensive update on critical U.S. healthcare and insurance issues including Medicaid policy, rural hospital challenges, Medicare Advantage scrutiny, FDA drug approvals, and public health dynamics.
CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.
President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.
